r&d

The report examines the performance of acquirers of 160 biotechnology firms and finds evidence that generally, the acquirers realize significant positive returns, which is positively correlated with the acquirers access to information about the research and development activities.

Using matched employer-employee longitudal data, the paper analyzes determinants of firm research and development (R&D), and in particular the impact of competition on R&D. Results indicate that competition is likely to contract from R&D expenditures.

The 2001 survey of industrial research and development (R&D) expenditures from the National Science Foundation (NSF) found that company funding of R&D totaled $181.6 billion in 2001. Before adjusting for inflation, the amount is up from the 2000 total of $180.4 billion. In constant dollars, industrial R&D expenditures declined less than one percent.

In response to the Virginia General Assemblys HB2760, the report provides eight recommendations that can build human capital and meet a second strategy that encourages collaboration and partnerships for research and development in Virginia.

The author examines whether for two different levels of technological spillovers, cooperative research and development (R&D) behavior voluntarily arises when firms have communication possibilities. Experimental results indicate that when technological spillovers are complete and subjects communicate, R&D decisions converge to the cooperative level, while in other cases R&D decisions converge towards the Nash equilibrium.

The study tests for the importance of cash flow on investment in fixed capital and research and development (R&D) using firm-level panel data in Great Britain and Germany. Results suggest that financial constraints are more significant in Britain, that they affect the decision to engage in R&D rather than the level of R&D spending by participants, and that consequently the British firms that do engage in R&D are a self-selected group where financing constraints tend to be less binding.

The study tests for the importance of cash flow on investment in fixed capital and research and development (R&D) using firm-level panel data in Great Britain and Germany. Results suggest that financial constraints are more significant in Britain, that they affect the decision to engage in R&D rather than the level of R&D spending by participants, and that consequently the British firms that do engage in R&D are a self-selected group where financing constraints tend to be less binding.

The paper draws on the knowledge-base implicit in ex post evaluations of publicly funded research and development (R&D) and other related conceptual and empirical studies to suggest a framework for the ex ante evaluation of the regional benefits from R&D projects.

The author assesses the properties of scale-free endogenous growth models in presence of use costs for the final users. Findings of the study indicate that under mild conditions use costs decrease the rate of vertical innovation and of overall economic growth.

The authors develop a real options model of research and development (R&D) valuation, which takes into account the uncertainty in the quality of the research output, the time and cost to completion, and the market demand for the R&D output. The model is then applied to study the problem of pharmaceutical under-investment in R&D for vaccines to treat diseases affecting the developing regions of the world.